A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- argenx
- Study ID
- NCT06637072
- Phase
- PHASE4
- Status
- Completed
Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Efgartigimod PH20 SC — BIOLOGICALSubcutaneous injection of efgartigimod PH20 SC
Study Details
This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.
Key Dates
- Start date
- Dec 10, 2024
- Status verified
- Apr 2026
- Primary completion
- Feb 19, 2026
- Completion
- Feb 19, 2026
Study Design
- Enrollment
- 23 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Efgartigimod PH20 SCParticipants start efgartigimod PH20 SC treatment after discontinuing IVIg
Primary Outcome Measure
Proportion of participants who begin treatment with efgartigimod PH20 SC within 1 week after stopping IVIg therapy and are still receiving efgartigimod PH20 SC at the end of the 12-week treatment period [ Time Frame: Up to 12 weeks ]
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| MedStar Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | - |
| Neurology Associates PA | Maitland | Florida | 32751 | - |
| Visionary Investigators Network | Miami | Florida | 33180 | - |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | - |
| Velocity Clinical Research | Lafayette | Louisiana | 70508 | - |
| SRI International - ClinEdge | Plymouth | Michigan | 48170 | - |
| Velocity Clinical Research | Raleigh | North Carolina | 27607 | - |
| Erlanger Neuroscience Institute | Chattanooga | Tennessee | 37403 | - |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | - |
| National Neuromuscular Research Institute | Austin | Texas | 78759 | - |
| Horizon Clinical Research: Gill Neuroscience | Cypress | Texas | 21216 | - |
| Northwest Houston Neurology - Cypress | Cypress | Texas | 77429 | - |
| Cedar Health Research - Dallas | Dallas | Texas | 75251 | - |
Find similar trials in Washington D.C., DC
Related Studies
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PHASE3 · Recruiting · Sanofi · Homewood, Alabama
- A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PHASE3 · Recruiting · Kedrion S.p.A. · Tampa, Florida
- A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)PHASE3 · Recruiting · Dianthus Therapeutics · Birmingham, Alabama
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPPHASE3 · Recruiting · argenx · Rancho Mirage, California